Neutrophil Vesicles as a novel autologous regenerative therapeutic for joint disease.

中性粒细胞囊泡作为一种新型自体再生疗法治疗关节疾病。

基本信息

  • 批准号:
    MR/P026362/1
  • 负责人:
  • 金额:
    $ 30.06万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2017
  • 资助国家:
    英国
  • 起止时间:
    2017 至 无数据
  • 项目状态:
    已结题

项目摘要

There is an unmet need for the treatment of rheumatoid arthritis since a significant proportion of patients do not respond to current therapies (~30%): this is evident from clinical trials and is even more acute in the community, where patients are 'not chosen' and comorbidities like obesity and diabetes increment the extent of therapeutic failures. As such, new approaches to improve prognosis and impact on patient quality of life are necessary. At the same time, as RA is diffuse in the adult population (1 in 20) better disease control can reduce the current health economic burden to our society (between 1 and 2.5% of GDP), determined by medicine and care costs as well as by loss of working hours.To address this clinical need, we propose herein a research project to establish the biology to underpin the future development of an innovative autologous therapy for rheumatoid arthritis patients. This therapeutic opportunity comes from the use of vesicles (bubbles) that can be generated from white blood cells that circulate in the blood together with red blood cells and can also reach the inflamed joint. In fact, we have quantified an enrichment of specific bubbles in the joint of rheumatoid arthritis patients and, to our surprise, reported that they protected the joint from inflammation and the cartilage from degradation.With this grant application we propose to study in experimental settings how these bubbles work; definition of the mechanisms activated by these bubbles to protect the joint can open avenues for developing an innovative autologous therapy: that is, we envisage a future scenario where rheumatoid arthritis patients will come to an out-patient clinic to donate their own white blood cells for the generation of bubbles which will then be injected into their own inflamed joint to exert anti-arthritic and analgesic effects. However, to accomplish this futuristic vision we must - 1) Understand the processes activated/modulated by the bubbles in the arthritic joint; 2) Define how many bubbles are required, an how often must be administered, to produce the beneficial effects on the joint;3) Establish efficacy of the bubbles not only in experimental animals but also on human cartilage.Completion of this project with a successful outcome will pave the way to the development phase for this innovative therapy, a path we will take with the guidance and advice of important players in the field, like the Cell and Gene Therapy Catapult and the MHRA, both of which have already been engaged.
类风湿关节炎的治疗需求尚未得到满足,因为相当大比例的患者对目前的治疗没有反应(约30%):这从临床试验中可以明显看出,在社区中甚至更为严重,患者“未被选择”,肥胖和糖尿病等合并症增加了治疗失败的程度。因此,改善预后和影响患者生活质量的新方法是必要的。与此同时,由于类风湿性关节炎在成年人中是弥漫性的(1 / 20),更好的疾病控制可以减少当前社会的卫生经济负担(占GDP的1%至2.5%),这是由药品和护理费用以及工作时间损失决定的。为了满足这一临床需求,我们在此提出一项研究项目,以建立生物学基础,以支持未来发展一种创新的自体治疗类风湿性关节炎患者。这种治疗机会来自于使用由白细胞产生的囊泡(气泡),这些白细胞与红细胞一起在血液中循环,也可以到达发炎的关节。事实上,我们已经量化了类风湿关节炎患者关节中特定气泡的富集,令我们惊讶的是,它们可以保护关节免受炎症和软骨降解。通过这项拨款申请,我们建议在实验环境中研究这些气泡是如何工作的;通过这些气泡激活保护关节的机制的定义可以为开发创新的自体治疗开辟道路:也就是说,我们设想未来的场景,类风湿关节炎患者将来到门诊捐献自己的白细胞来产生气泡,然后将其注射到他们自己发炎的关节中,以发挥抗关节炎和镇痛作用。然而,为了实现这一未来的愿景,我们必须- 1)了解关节炎关节中的气泡激活/调节的过程;2)确定需要多少气泡,以及必须多久注射一次,才能对关节产生有益的影响;3)建立气泡在实验动物和人体软骨上的功效。该项目的成功完成将为这种创新疗法的开发阶段铺平道路,我们将在该领域重要参与者的指导和建议下走这条道路,如细胞和基因治疗弹弓和MHRA,两者都已经参与其中。

项目成果

期刊论文数量(9)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Neutrophil Microvesicles from Healthy Control and Rheumatoid Arthritis Patients Prevent the Inflammatory Activation of Macrophages.
  • DOI:
    10.1016/j.ebiom.2018.02.003
  • 发表时间:
    2018-03
  • 期刊:
  • 影响因子:
    11.1
  • 作者:
    Rhys HI;Dell'Accio F;Pitzalis C;Moore A;Norling LV;Perretti M
  • 通讯作者:
    Perretti M
Annexin A1 attenuates cardiac diastolic dysfunction in mice with inflammatory arthritis.
WNT3A-loaded exosomes enable cartilage repair.
  • DOI:
    10.1002/jev2.12088
  • 发表时间:
    2021-05
  • 期刊:
  • 影响因子:
    16
  • 作者:
    Thomas BL;Eldridge SE;Nosrati B;Alvarez M;Thorup AS;Nalesso G;Caxaria S;Barawi A;Nicholson JG;Perretti M;Gaston-Massuet C;Pitzalis C;Maloney A;Moore A;Jupp R;Dell'Accio F
  • 通讯作者:
    Dell'Accio F
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mauro Perretti其他文献

Molecular determinants of monosodium urate crystal-induced murine peritonitis: a role for endogenous mast cells and a distinct requirement for endothelial-derived selectins.
尿酸钠晶体诱导的小鼠腹膜炎的分子决​​定因素:内源性肥大细胞的作用和对内皮源性选择素的独特需求。
  • DOI:
  • 发表时间:
    1997
  • 期刊:
  • 影响因子:
    3.5
  • 作者:
    Stephen J. Getting;R. J. Flower;Luca Parente;Rinaldo De;Mé Dicis;André Lussier;Barry A. Woliztky;Marco A. Martins;Mauro Perretti
  • 通讯作者:
    Mauro Perretti
Aspirin-triggered 15-epi-lipoxin A<sub>4</sub> signals through FPR2/ALX in vascular smooth muscle cells and protects against intimal hyperplasia after carotid ligation
  • DOI:
    10.1016/j.ijcard.2014.11.010
  • 发表时间:
    2015-01-20
  • 期刊:
  • 影响因子:
  • 作者:
    Marcelo H. Petri;Andrés Laguna-Fernandez;Chi-Nan Tseng;Ulf Hedin;Mauro Perretti;Magnus Bäck
  • 通讯作者:
    Magnus Bäck
Controlling Inflammation: a Fat Chance? Explaining the Beneficial Effects
控制炎症:机会很大吗?
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
    R. J. Flower;Mauro Perretti
  • 通讯作者:
    Mauro Perretti
Immune resolution mechanisms in inflammatory arthritis
炎症性关节炎中的免疫消退机制
  • DOI:
    10.1038/nrrheum.2016.193
  • 发表时间:
    2017-01-05
  • 期刊:
  • 影响因子:
    32.700
  • 作者:
    Mauro Perretti;Dianne Cooper;Jesmond Dalli;Lucy V. Norling
  • 通讯作者:
    Lucy V. Norling
Glucocorticoid Receptor Activation Reduces Cd11b and Cd49d Levels on Murine Eosinophils Characterization and Functional Relevance Materials and Methods
糖皮质激素受体激活可降低小鼠嗜酸性粒细胞表征和功能相关性的 Cd11b 和 Cd49d 水平 材料和方法
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Lina H. K. Lim;R. J. Flower;Mauro Perretti;Anuk Das
  • 通讯作者:
    Anuk Das

Mauro Perretti的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mauro Perretti', 18)}}的其他基金

Repurposing Alpha-1-antitrypsin as a treatment for post-traumatic osteoarthritis
重新利用 Alpha-1-抗胰蛋白酶治疗创伤后骨关节炎
  • 批准号:
    MR/Y013883/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.06万
  • 项目类别:
    Research Grant
MRC IAA 2021 Queen Mary University of London
MRC IAA 2021 伦敦玛丽女王大学
  • 批准号:
    MR/X502893/1
  • 财政年份:
    2022
  • 资助金额:
    $ 30.06万
  • 项目类别:
    Research Grant
Treating the host in Dengue: mediators and pathways of resolution as a new therapeutic paradigm
治疗登革热宿主:介质和解决途径作为新的治疗范式
  • 批准号:
    MR/N017544/1
  • 财政年份:
    2016
  • 资助金额:
    $ 30.06万
  • 项目类别:
    Research Grant
Translating the Resolution of Inflammation: MC3 in human arthritis synovia
转化炎症消退:人类关节炎滑液中的 MC3
  • 批准号:
    MR/K013068/1
  • 财政年份:
    2013
  • 资助金额:
    $ 30.06万
  • 项目类别:
    Research Grant

相似海外基金

Development and deployment of novel strategies to dramatically increase the efficiency of intracellular delivery of extracellular vesicles
开发和部署新策略以显着提高细胞外囊泡的细胞内递送效率
  • 批准号:
    23KJ1368
  • 财政年份:
    2023
  • 资助金额:
    $ 30.06万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
The role of alcohol-associated microbiota membrane vesicles in mucosal immunity
酒精相关微生物膜囊泡在粘膜免疫中的作用
  • 批准号:
    10751767
  • 财政年份:
    2023
  • 资助金额:
    $ 30.06万
  • 项目类别:
Understanding the Heterogeneity of Nanoscale Extracellular Vesicles, Exomeres, and Supermeres using Next Generation Optical Nanotweezers
使用下一代光学纳米镊子了解纳米级细胞外囊泡、外泌体和 Supermeres 的异质性
  • 批准号:
    10714221
  • 财政年份:
    2023
  • 资助金额:
    $ 30.06万
  • 项目类别:
Mass spectrometry for highly sensitive and sample-sparing analysis of extracellular vesicles in liver diseases
用于肝脏疾病细胞外囊泡高灵敏度和样品节省分析的质谱法
  • 批准号:
    10736006
  • 财政年份:
    2023
  • 资助金额:
    $ 30.06万
  • 项目类别:
The role of extracellular vesicles in keratoconus pathogenesis
细胞外囊泡在圆锥角膜发病机制中的作用
  • 批准号:
    10595121
  • 财政年份:
    2023
  • 资助金额:
    $ 30.06万
  • 项目类别:
Brain derived extracellular vesicles-mediated neurotoxicity of deltamethrin
溴氰菊酯脑源性细胞外囊泡介导的神经毒性
  • 批准号:
    10679858
  • 财政年份:
    2023
  • 资助金额:
    $ 30.06万
  • 项目类别:
Abnormal Extracellular Vesicles and Particles from Human Islets Impact T1D progression
来自人类胰岛的异常细胞外囊泡和颗粒影响 T1D 进展
  • 批准号:
    10754074
  • 财政年份:
    2023
  • 资助金额:
    $ 30.06万
  • 项目类别:
Outer Membrane Vesicles in Shiga Toxin-Mediated Inflammatory and Thrombotic Responses Leading to Systemic Disease
志贺毒素介导的导致全身性疾病的炎症和血栓反应中的外膜囊泡
  • 批准号:
    10668016
  • 财政年份:
    2023
  • 资助金额:
    $ 30.06万
  • 项目类别:
The pathogenic roles of GSDMD-dependent gut epithelium extracellular vesicles in IBD
GSDMD依赖性肠上皮细胞外囊泡在IBD中的致病作用
  • 批准号:
    10853519
  • 财政年份:
    2023
  • 资助金额:
    $ 30.06万
  • 项目类别:
Homogenized, engineered extracellular vesicles for intracranial targeting
用于颅内靶向的均质化、工程化细胞外囊泡
  • 批准号:
    10659682
  • 财政年份:
    2023
  • 资助金额:
    $ 30.06万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了